How best to develop a liquid biopsy?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Veracyte’s nasal lung cancer test results raise questions
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Asco 2019 – Guardant and Grail square up
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Exact falls on Guardant’s liquid biopsy plans
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
